Cargando…
Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double‐blind, placebo‐controlled trial
BACKGROUND: Immunotherapy with peptide hydrolysates from Lolium perenne (LPP) is an alternative treatment for seasonal allergic rhinitis with or without asthma. The aim of this study was to assess the clinical efficacy and safety of a cumulative dose of 170 μg LPP administered subcutaneously over 3 ...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175232/ https://www.ncbi.nlm.nih.gov/pubmed/29512827 http://dx.doi.org/10.1111/all.13433 |
_version_ | 1783361461173616640 |
---|---|
author | Mösges, R. Bachert, C. Panzner, P. Calderon, M. A. Haazen, L. Pirotton, S. Wathelet, N. Durham, S. R. Bonny, M.‐A. Legon, T. von Frenckell, R. Pfaar, O. Shamji, M. H. |
author_facet | Mösges, R. Bachert, C. Panzner, P. Calderon, M. A. Haazen, L. Pirotton, S. Wathelet, N. Durham, S. R. Bonny, M.‐A. Legon, T. von Frenckell, R. Pfaar, O. Shamji, M. H. |
author_sort | Mösges, R. |
collection | PubMed |
description | BACKGROUND: Immunotherapy with peptide hydrolysates from Lolium perenne (LPP) is an alternative treatment for seasonal allergic rhinitis with or without asthma. The aim of this study was to assess the clinical efficacy and safety of a cumulative dose of 170 μg LPP administered subcutaneously over 3 weeks. METHODS: In a randomized, double‐blind, placebo‐controlled trial, 554 adults with grass pollen rhinoconjunctivitis were randomized (1:2 ratio) to receive 8 subcutaneous injections of placebo or 170 μg LPP administered in increasing doses in 4 visits over 3 weeks. The primary outcome was the combined symptom and medication score (CSMS) measured over the peak pollen season. Reactivity to conjunctival provocation test (CPT) and quality of life (QOL) was assessed as secondary endpoints. RESULTS: The mean reduction in CSMS in the LPP vs placebo group was −15.5% (P = .041) during the peak period and −17.9% (P = .029) over the entire pollen season. LPP‐treated group had a reduced reactivity to CPT (P < .001) and, during the pollen season, a lower rhinoconjunctivitis QOL global score (P = .005) compared with placebo group. Mostly mild and WAO grade 1 early systemic reaction (ESR) were observed ≤30 minutes in 10.5% of LPP‐treated patients, whereas 3 patients with a medical history of asthma (<1%) experienced a serious ESR that resolved with rescue medication. CONCLUSION: Lolium perenne pollen peptides administered over 3 weeks before the grass pollen season significantly reduced seasonal symptoms and was generally safe and well‐tolerated. |
format | Online Article Text |
id | pubmed-6175232 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-61752322018-10-15 Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double‐blind, placebo‐controlled trial Mösges, R. Bachert, C. Panzner, P. Calderon, M. A. Haazen, L. Pirotton, S. Wathelet, N. Durham, S. R. Bonny, M.‐A. Legon, T. von Frenckell, R. Pfaar, O. Shamji, M. H. Allergy ORIGINAL ARTICLES BACKGROUND: Immunotherapy with peptide hydrolysates from Lolium perenne (LPP) is an alternative treatment for seasonal allergic rhinitis with or without asthma. The aim of this study was to assess the clinical efficacy and safety of a cumulative dose of 170 μg LPP administered subcutaneously over 3 weeks. METHODS: In a randomized, double‐blind, placebo‐controlled trial, 554 adults with grass pollen rhinoconjunctivitis were randomized (1:2 ratio) to receive 8 subcutaneous injections of placebo or 170 μg LPP administered in increasing doses in 4 visits over 3 weeks. The primary outcome was the combined symptom and medication score (CSMS) measured over the peak pollen season. Reactivity to conjunctival provocation test (CPT) and quality of life (QOL) was assessed as secondary endpoints. RESULTS: The mean reduction in CSMS in the LPP vs placebo group was −15.5% (P = .041) during the peak period and −17.9% (P = .029) over the entire pollen season. LPP‐treated group had a reduced reactivity to CPT (P < .001) and, during the pollen season, a lower rhinoconjunctivitis QOL global score (P = .005) compared with placebo group. Mostly mild and WAO grade 1 early systemic reaction (ESR) were observed ≤30 minutes in 10.5% of LPP‐treated patients, whereas 3 patients with a medical history of asthma (<1%) experienced a serious ESR that resolved with rescue medication. CONCLUSION: Lolium perenne pollen peptides administered over 3 weeks before the grass pollen season significantly reduced seasonal symptoms and was generally safe and well‐tolerated. John Wiley and Sons Inc. 2018-06-21 2018-09 /pmc/articles/PMC6175232/ /pubmed/29512827 http://dx.doi.org/10.1111/all.13433 Text en © 2018 The Authors. Allergy Published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | ORIGINAL ARTICLES Mösges, R. Bachert, C. Panzner, P. Calderon, M. A. Haazen, L. Pirotton, S. Wathelet, N. Durham, S. R. Bonny, M.‐A. Legon, T. von Frenckell, R. Pfaar, O. Shamji, M. H. Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double‐blind, placebo‐controlled trial |
title | Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double‐blind, placebo‐controlled trial |
title_full | Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double‐blind, placebo‐controlled trial |
title_fullStr | Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double‐blind, placebo‐controlled trial |
title_full_unstemmed | Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double‐blind, placebo‐controlled trial |
title_short | Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double‐blind, placebo‐controlled trial |
title_sort | short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: a randomized, multicenter, double‐blind, placebo‐controlled trial |
topic | ORIGINAL ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175232/ https://www.ncbi.nlm.nih.gov/pubmed/29512827 http://dx.doi.org/10.1111/all.13433 |
work_keys_str_mv | AT mosgesr shortcourseofgrassallergenpeptidesimmunotherapyover3weeksreducesseasonalsymptomsinallergicrhinoconjunctivitiswithwithoutasthmaarandomizedmulticenterdoubleblindplacebocontrolledtrial AT bachertc shortcourseofgrassallergenpeptidesimmunotherapyover3weeksreducesseasonalsymptomsinallergicrhinoconjunctivitiswithwithoutasthmaarandomizedmulticenterdoubleblindplacebocontrolledtrial AT panznerp shortcourseofgrassallergenpeptidesimmunotherapyover3weeksreducesseasonalsymptomsinallergicrhinoconjunctivitiswithwithoutasthmaarandomizedmulticenterdoubleblindplacebocontrolledtrial AT calderonma shortcourseofgrassallergenpeptidesimmunotherapyover3weeksreducesseasonalsymptomsinallergicrhinoconjunctivitiswithwithoutasthmaarandomizedmulticenterdoubleblindplacebocontrolledtrial AT haazenl shortcourseofgrassallergenpeptidesimmunotherapyover3weeksreducesseasonalsymptomsinallergicrhinoconjunctivitiswithwithoutasthmaarandomizedmulticenterdoubleblindplacebocontrolledtrial AT pirottons shortcourseofgrassallergenpeptidesimmunotherapyover3weeksreducesseasonalsymptomsinallergicrhinoconjunctivitiswithwithoutasthmaarandomizedmulticenterdoubleblindplacebocontrolledtrial AT watheletn shortcourseofgrassallergenpeptidesimmunotherapyover3weeksreducesseasonalsymptomsinallergicrhinoconjunctivitiswithwithoutasthmaarandomizedmulticenterdoubleblindplacebocontrolledtrial AT durhamsr shortcourseofgrassallergenpeptidesimmunotherapyover3weeksreducesseasonalsymptomsinallergicrhinoconjunctivitiswithwithoutasthmaarandomizedmulticenterdoubleblindplacebocontrolledtrial AT bonnyma shortcourseofgrassallergenpeptidesimmunotherapyover3weeksreducesseasonalsymptomsinallergicrhinoconjunctivitiswithwithoutasthmaarandomizedmulticenterdoubleblindplacebocontrolledtrial AT legont shortcourseofgrassallergenpeptidesimmunotherapyover3weeksreducesseasonalsymptomsinallergicrhinoconjunctivitiswithwithoutasthmaarandomizedmulticenterdoubleblindplacebocontrolledtrial AT vonfrenckellr shortcourseofgrassallergenpeptidesimmunotherapyover3weeksreducesseasonalsymptomsinallergicrhinoconjunctivitiswithwithoutasthmaarandomizedmulticenterdoubleblindplacebocontrolledtrial AT pfaaro shortcourseofgrassallergenpeptidesimmunotherapyover3weeksreducesseasonalsymptomsinallergicrhinoconjunctivitiswithwithoutasthmaarandomizedmulticenterdoubleblindplacebocontrolledtrial AT shamjimh shortcourseofgrassallergenpeptidesimmunotherapyover3weeksreducesseasonalsymptomsinallergicrhinoconjunctivitiswithwithoutasthmaarandomizedmulticenterdoubleblindplacebocontrolledtrial |